GlassScriptPhysician profile
Drew Venuto
NPI 1053065243
$1,959.43
in general payments reported to CMS, 2019-2025
23 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $276 · 2023: $590 · 2024: $577 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $486.89 | 2022-2025 | |
| Pfizer INC. | $198.57 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $149.61 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $148.55 | 2022-2025 | Eliquis, Camzyos |
| Medical Device Business Services, INC. | $137.01 | 2022 | |
| Novo Nordisk INC | $124.93 | 2024-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $121.15 | 2022-2023 | Xarelto |
| Amgen INC. | $120.18 | 2023-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $59.67 | 2025 | Watchman |
| Abiomed | $55.09 | 2024-2025 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $45.94 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $39.84 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.62 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $34.66 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $33.51 | 2024-2025 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $29.88 | 2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $25.99 | 2024 | Opsumit |
| Vital Connect, INC | $21.98 | 2023 | Vitalpatch Rtm |
| Kiniksa Pharmaceuticals, LTD. | $20.11 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $19.02 | 2025 | Nexletol |
| Daiichi Sankyo INC. | $17.62 | 2023 | Injectafer |
| Cvrx, INC. | $16.26 | 2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.35 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Venuto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.